Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Retrophin Inc (NASDAQ:RTRX)

19.99
Delayed Data
As of Jun 23
 +0.28 / +1.42%
Today’s Change
15.55
Today|||52-Week Range
24.57
+5.60%
Year-to-Date
Pharma Bro's Trial to Begin Monday
Jun 23 / TheStreet.com - Paid Partner Content
Martin Shkreli fraud trial begins next week
Jun 23 / CNNMoney.com

Today’s Trading

Previous close19.71
Today’s open19.64
Day’s range19.22 - 20.02
Volume550,138
Average volume (3 months)356,476
Market cap$752.4M
Dividend yield--
Data as of 4:00pm ET, 06/23/2017

Growth & Valuation

Earnings growth (last year)-140.69%
Earnings growth (this year)+11.82%
Earnings growth (next 5 years)+137.00%
Revenue growth (last year)+33.74%
P/E ratioNM
Price/Sales5.43
Price/Book2.43

Competitors

 Today’s
change
Today’s
% change
NDRMNeuroderm Ltd+0.75+2.60%
EDITEditas Medicine Inc+0.41+2.34%
EPZMEpizyme Inc+1.05+7.69%
MYOVMyovant Sciences Ltd-0.07-0.60%
Data as of 4:00pm ET, 06/23/2017

Financials

Next reporting dateAugust 15, 2017
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$133.6M
Annual profit (last year)-$47.9M
Net profit margin-35.86%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stephen J. Aselage
Chief Operating Officer
Neil McFarlane
Corporate headquarters
San Diego, California

Forecasts